Eledon Pharmaceuticals Enacts Key Proposals and Board Changes
Company Announcements

Eledon Pharmaceuticals Enacts Key Proposals and Board Changes

Eledon Pharmaceuticals (ELDN) just unveiled an announcement.

Eledon Pharmaceuticals, Inc. stockholders convened on July 10, 2024, approving key proposals that will shape the company’s future. They voted to increase the share cap of the 2020 Incentive Plan by 3.5 million and extend its duration by over a year. Additionally, Dr. Steven Perrin and Dr. June Lee were elected as Class I Directors, while KMJ Corbin & Company LLP was ratified as the independent accounting firm. Following Walter Ogier’s retirement, the board underwent a reshuffle, appointing new members to the Audit, Compensation, and Nominating and Corporate Governance Committees, ensuring compliance with Nasdaq’s independence standards.

For a thorough assessment of ELDN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyEledon Pharmaceuticals price target lowered to $20.50 from $28 at Ladenburg
TipRanks Auto-Generated NewsdeskEledon Pharmaceuticals Reports Strong Q3 2024 Results
TheFlyEledon Pharmaceuticals reports Q3 EPS (32c), consensus (31c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App